Liu Z. et. al., 2018 Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients., 10.1158/1078-0432.CCR-17-1350, Clin. Can. Res,, Apr 30, 2018 ➔

Mu L. et. al., 2018 The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas, 10.3389/fnmol.2018.00082, Front. Mol. Neurosci., Mar 28, 2018 ➔

Arend R.C. et. al., 2018 Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma., 10.1158/1541-7786.MCR-17-0594, Mol. Can. Res., Mar 08, 2018 ➔

Nakazawa Y. et. al., Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer, 10.1038/s41598-018-22340-7, Sci. Reports, Mar 05, 2018 ➔

Sampath S. et. al., Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients, 10.18632/oncotarget.24397 , Oncotarget, Feb 02, 2018 ➔

Daemen A. et. al., HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors, 10.1186/s13058-018-0933-y, Breast Can. Res., Jan 30, 2018 ➔

Kessous R. et. al., Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer., 10.1016/j.ygyno.2018.01.017, Gynecol. Oncol., Jan 29, 2018 ➔

Ricca J.M. et. al., Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy., 10.1016/j.ymthe.2018.01.019, Mol. Therapy, Jan 25, 2018 ➔

Janse Van Rensburg H.J. et. al., The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1., 10.1158/0008-5472.CAN-17-3139, Can. Res., Jan 16, 2018 ➔

Luo N. et al., DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer, 10.1038/s41467-017-02630-w, Nat. Commun., Jan 16, 2018 ➔

Zhao X. et. al., B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors, 10.1016/j.ymthe.2018.01.007, Mol. Therapy, Jan 16, 2018 ➔

Michaelsen S.R. et. al., Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival, 10.1007/s11060-017-2739-7, J. Neurooncol., Jan 05, 2018 ➔

Zapka P. et al., Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms., 10.1093/jnen/nlx106, J. Neuropathol. Exp. Neurol., Dec 11, 2017 ➔

Oweida A. et. al., Response to stereotactic ablative radiotherapy in a novel orthotopic model of non-small cell lung cancer, 10.18632/oncotarget.22727, Oncotarget, Nov 28, 2017 ➔

Lampis A. et al., MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma, 10.1053/j.gastro.2017.10.043, Gatroenterology, Nov 04, 2017 ➔